Discover free eBooks, guides and med spa templates on our new resources page

ICD11

Neoplasms (C00–D49)

Get Codes

Neoplasms is a chapter in ICD-11 that encompasses diseases characterized by abnormal and uncontrolled growth of cells, which can form tumors or masses and may interfere with normal body functions. These conditions include both benign and malignant growths, as well as neoplasms of uncertain or unknown behavior. The chapter classifies neoplasms according to their site of origin, tissue type, and biological behavior, providing a structured approach to understanding the wide spectrum of tumor-related conditions.

This chapter plays a crucial role in cancer diagnosis, treatment planning, research, and epidemiological tracking. It includes solid tumors and hematological malignancies, such as leukemias and lymphomas, and supports standardized reporting across healthcare systems. Accurate classification of neoplasms helps clinicians assess prognosis, select appropriate therapies, and monitor disease outcomes, while also enabling public health authorities to analyze cancer trends and develop effective prevention and control strategies.

Start Using ICD Codes in Practice

Move from reference to real use. Apply ICD codes directly within patient records, documentation, and reporting in Pabau.

Get Started

Frequently asked questions

This chapter covers benign, malignant, and in situ neoplasms, classified according to anatomical site, behavior, and histopathology.

It includes solid tumors, hematological malignancies such as leukemia and lymphoma, and related neoplastic conditions.

Yes. ICD-11 includes in situ neoplasms and certain precancerous conditions that have clinical relevance for monitoring and treatment.

ICD-11 aligns closely with contemporary tumor classification systems and incorporates advances in pathology and cancer biology.

Yes. Primary tumors and metastatic sites are coded separately to reflect disease extent and clinical management.

Accurate coding supports cancer registries, treatment planning, outcomes research, reimbursement, and population-level cancer surveillance.

×